Cargando…

Prognostic indices in stereotactic radiotherapy of brain metastases of non-small cell lung cancer

BACKGROUND: Our purpose was to analyze the long-term clinical outcome and to identify prognostic factors after Linac-based stereotactic radiosurgery (SRS) or fractionated stereotactic radiotherapy (FSRT) on patients with brain metastases (BM) from non-small cell lung cancer (NSCLC). MATERIALS AND ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaul, David, Angelidis, Alexander, Budach, Volker, Ghadjar, Pirus, Kufeld, Markus, Badakhshi, Harun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4661968/
https://www.ncbi.nlm.nih.gov/pubmed/26611493
http://dx.doi.org/10.1186/s13014-015-0550-1
_version_ 1782403086936965120
author Kaul, David
Angelidis, Alexander
Budach, Volker
Ghadjar, Pirus
Kufeld, Markus
Badakhshi, Harun
author_facet Kaul, David
Angelidis, Alexander
Budach, Volker
Ghadjar, Pirus
Kufeld, Markus
Badakhshi, Harun
author_sort Kaul, David
collection PubMed
description BACKGROUND: Our purpose was to analyze the long-term clinical outcome and to identify prognostic factors after Linac-based stereotactic radiosurgery (SRS) or fractionated stereotactic radiotherapy (FSRT) on patients with brain metastases (BM) from non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: We performed a retrospective analysis of survival on 90 patients who underwent SRS or FSRT of intracranial NSCLC metastases between 04/2004 and 05/2014 that had not undergone prior surgery or whole brain radiotherapy (WBRT) for BM. Follow-up data was analyzed until May 2015. Potential prognostic factors were examined in univariable and multivariable analyses. The Golden Grading System (GGS), the disease-specific graded prognostic assessment (DS-GPA), the RADES II prognostic index as well as the NSCLC-specific index proposed by Rades et al. in 2013 (NSCLC-RADES) were calculated and their predictive values were tested in univariable analysis. RESULTS: The median follow-up time of the surviving patients was 14 months. The overall survival (OS) rate was 51 % after 6 months and 29.9 % after 12 months. Statistically significant factors of better OS after univariable analysis were lower International Union Against Cancer (UICC) stage at first diagnosis, histology of adenocarcinoma, prior surgery of the primary tumor and lower total BM volume. After multivariable analysis adenocarcinoma histology remained a significant factor; higher Karnofsky Performance Score (KPS) and the presence of extracranial metastases (ECM) were also significant. The RADES II and the NSCLC-RADES indices were significant predictors of OS. However, the NSCLC-RADES failed to differentiate between intermediate- and low-risk patients. The DS-GPA and GGS were not statistically significant predictors of survival in univariable analysis. CONCLUSION: The ideal prognostic index has not been defined yet. We believe that more specific indices will be developed in the future. Our results indicate that the histologic subtype of NSCLC could add to the prognostic value of specialized future indices. The RADES II index had the highest predictive value in the examined patient cohort.
format Online
Article
Text
id pubmed-4661968
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-46619682015-11-28 Prognostic indices in stereotactic radiotherapy of brain metastases of non-small cell lung cancer Kaul, David Angelidis, Alexander Budach, Volker Ghadjar, Pirus Kufeld, Markus Badakhshi, Harun Radiat Oncol Research BACKGROUND: Our purpose was to analyze the long-term clinical outcome and to identify prognostic factors after Linac-based stereotactic radiosurgery (SRS) or fractionated stereotactic radiotherapy (FSRT) on patients with brain metastases (BM) from non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: We performed a retrospective analysis of survival on 90 patients who underwent SRS or FSRT of intracranial NSCLC metastases between 04/2004 and 05/2014 that had not undergone prior surgery or whole brain radiotherapy (WBRT) for BM. Follow-up data was analyzed until May 2015. Potential prognostic factors were examined in univariable and multivariable analyses. The Golden Grading System (GGS), the disease-specific graded prognostic assessment (DS-GPA), the RADES II prognostic index as well as the NSCLC-specific index proposed by Rades et al. in 2013 (NSCLC-RADES) were calculated and their predictive values were tested in univariable analysis. RESULTS: The median follow-up time of the surviving patients was 14 months. The overall survival (OS) rate was 51 % after 6 months and 29.9 % after 12 months. Statistically significant factors of better OS after univariable analysis were lower International Union Against Cancer (UICC) stage at first diagnosis, histology of adenocarcinoma, prior surgery of the primary tumor and lower total BM volume. After multivariable analysis adenocarcinoma histology remained a significant factor; higher Karnofsky Performance Score (KPS) and the presence of extracranial metastases (ECM) were also significant. The RADES II and the NSCLC-RADES indices were significant predictors of OS. However, the NSCLC-RADES failed to differentiate between intermediate- and low-risk patients. The DS-GPA and GGS were not statistically significant predictors of survival in univariable analysis. CONCLUSION: The ideal prognostic index has not been defined yet. We believe that more specific indices will be developed in the future. Our results indicate that the histologic subtype of NSCLC could add to the prognostic value of specialized future indices. The RADES II index had the highest predictive value in the examined patient cohort. BioMed Central 2015-11-26 /pmc/articles/PMC4661968/ /pubmed/26611493 http://dx.doi.org/10.1186/s13014-015-0550-1 Text en © Kaul et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Kaul, David
Angelidis, Alexander
Budach, Volker
Ghadjar, Pirus
Kufeld, Markus
Badakhshi, Harun
Prognostic indices in stereotactic radiotherapy of brain metastases of non-small cell lung cancer
title Prognostic indices in stereotactic radiotherapy of brain metastases of non-small cell lung cancer
title_full Prognostic indices in stereotactic radiotherapy of brain metastases of non-small cell lung cancer
title_fullStr Prognostic indices in stereotactic radiotherapy of brain metastases of non-small cell lung cancer
title_full_unstemmed Prognostic indices in stereotactic radiotherapy of brain metastases of non-small cell lung cancer
title_short Prognostic indices in stereotactic radiotherapy of brain metastases of non-small cell lung cancer
title_sort prognostic indices in stereotactic radiotherapy of brain metastases of non-small cell lung cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4661968/
https://www.ncbi.nlm.nih.gov/pubmed/26611493
http://dx.doi.org/10.1186/s13014-015-0550-1
work_keys_str_mv AT kauldavid prognosticindicesinstereotacticradiotherapyofbrainmetastasesofnonsmallcelllungcancer
AT angelidisalexander prognosticindicesinstereotacticradiotherapyofbrainmetastasesofnonsmallcelllungcancer
AT budachvolker prognosticindicesinstereotacticradiotherapyofbrainmetastasesofnonsmallcelllungcancer
AT ghadjarpirus prognosticindicesinstereotacticradiotherapyofbrainmetastasesofnonsmallcelllungcancer
AT kufeldmarkus prognosticindicesinstereotacticradiotherapyofbrainmetastasesofnonsmallcelllungcancer
AT badakhshiharun prognosticindicesinstereotacticradiotherapyofbrainmetastasesofnonsmallcelllungcancer